Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 2—February 2023
Synopsis

Changing Disease Course of Crimean-Congo Hemorrhagic Fever in Children, Turkey

Pembe Derin Oygar1, Sibel Laçinel Gürlevik, Erdal Sağ, Sare İlbay, Tekin Aksu, Osman Oğuz Demir, Yasemin Coşgun, Selin Aytaç Eyüpoğlu, Jale Karakaya, Şule Ünal Cangül, Ali Bülent Cengiz, and Yasemin ÖzsürekciComments to Author 
Author affiliations: Hacettepe University, Ankara, Turkey (P.D. Oygar, S.L. Gürlevik, E. Sağ, T. Aksu, O.O. Demir, S.A. Eyüpoğlu, J. Karakaya, Ş.Ü. Cangül, A.B. Cengiz, Y. Özsürekci); İhsan Doğramacı Children’s Hospital, Ankara (P.D. Oygar, S.L. Gürlevik, T. Aksu, O.O. Demir, S.A. Eyüpoğlu, Ş.Ü. Cangül, A.B. Cengiz, Y. Özsürekci); Ankara Training and Research Hospital, Ankara (E. Sağ); Hacettepe University Rheumatology Translational Medicine Laboratories, Ankara (S. İlbay); General Directorate of Public Health, Ministry of Health, Microbiology Reference and Biological Materials Laboratory, Ankara (Y. Coşgun)

Main Article

Table 2

Laboratory parameters for 12 pediatric case-patients with Crimean-Congo hemorrhagic fever at hospital admission and for 3 subsequent time intervals, Turkey*

Parameters, units Reference range Admission, median ±SD (min–max) 1st interval, median ±SD (min–max) 2nd interval, median ±SD (min–max) 3rd interval, median ±SD (min­–max)
Hemoglobin, g/dL
 11.1–14
 13.95 ±1.57
(11.30–16.60)
 13.90 ±1.74
(10.70–16.20)
 12.80 ±1.57
(9.40–15.30)
 12.70 ±2.07
(8.50–15.80)
Leukocytes, × 103 cells/μL
 5–13
 2.25 ±1.01
(1.10–4.70)
 1.85 ±0.42
(1.30–2.70)
 2.00 ±1.30
(1.10–4.10)
 3.60 ±1.97
(2.60–7.60)
Neutrophils, × 103 cells/μL
 5–13
 1.66 ±1.08
(0.25–3.89)
 1.28 ±0.59
(0.20–1.87)
 1.00 ±0.83
(0.33–2.96)
 2.04 ±1.36
(0.58–4.29)
Lymphocytes, × 103 cells/μL
 1–5
 0.46 ±0.26
(0.23–1.11)
 0.46 ±0.25
(0.21–1.00)
 0.64 ±0.50
(0.24 ±1.80)
 0.83 ±0.49
(0.38–1.93)
Platelets, × 103 μL
 159–388
 55.00 ±36.38 (13.00–144.00)
 40.50 ±39.34 (11.00–127.00)
 58.50 ±33.01 (22.00–116.00)
 91.00 ±52.18 (33.00–219.00)
aPTT, s
 22.5–32
 34.70 ±7.28
(14.80–44.90)
 33.10 ±6.92
(25.90–46.10)
 25.55 ±3.33
(20.20–29.50)
 21.90 ±4.90
(19.90–32.20)
INR
 0.8–1.2
 1.30 ±0.23
(0.96–1.70)
 1.30 ±0.27
(0.96–1.89)
 0.92 ±0.14
(0.85–1.37)
 0.92 ±0.05
(0.72–1.00)
Fibrinogen, mg/dL
 180–350
 209.81 ±48.47 (153.68–323.81)
 198.33 ±48.97 (140.84–303.00)
 231.28 ±6,848.78 (170.91–22,691.00)
 213.40 ±41.43 (153.29–286.21)
D-dimer, mg/dL
 0–0.55
 7.16 ±27.89
(1.48–67.15)
 5.71 ±26.28
(1.89–78.48)
 1.91 ±1.03
(0.79–4.45)
 2.21 ±3.35
(0.56–10.68)
ALT, U/L
 <39
 65.00 ±159.188 (18.00–580.00)
 58.50 ±174.94 (19.00–635.00)
 129.00 ±86.74 (32.00–354.00)
 143.00 ±79.78 (29.00–253.00)
AST, U/L
 <51
 162.50 ±443.42 (45.00–1648.00)
 159.50 ±500.83 (47.00–1,818.00)
 187.50 ±131.10 (72.00–519.00)
 140.00 ±90.54 (52.00–359.00)
CK, U/L
 <145
 205.00 ±2,237.28 (69.00–7,297.00)
 266.50 ±2,136.11 (54.00–6,292.00)
 130.50 ±116.01 (60.00–364.00)
 96.00 ±99.61 (42.00–301.00)
Triglyceride, mg/dL
 <150
 93.50 ±53.29 (43.00–192.00)
 118.00 ±35.28 (46.00–142.00)
 190.00 ±56.69 (130.00–304.00)
 220.50 ±92.75 (91.00–378.00)
LDH, U/L
 110–295
 577 ±528.32 (288.00–2,091.00)
 651.00 ±49.69 (295.00–1,757.00)
 525.00 ±214.18 (313.00–1,089.00)
 428.00 ±206.11 (212.00–848.00)
C-reactive protein, mg/dL
 0–0.5
 1.24 ±2.08
(0.10–6.95)
 0.54 ±0.56
(0.12–1.85)
 0.17 ±0.10
(0.03–0.39)
 0.14 ±0.10
(0.02–0.4)
ESR, mm/h
 0–20
 3.00 ±5.54
(2.00–21.00)
 8.00 ±7.79
(2.00–23.00)
 22.00 ±12.74
(12.00–49.00)
 36.00 ±15.40
(7.00–56.00)
Ferritin, μL
 11–307
 2,816.00 ±5,779.20 (309.00–21,690.00)
 4,257.00 ±12,330.80 (648–40,455)
 2,762.50 ±5,423.00 (558.00–18,772.00)
 1,619.50 ±2,822.24 (404.00–9,981.00)
*First time interval, 68–72 h after baseline; second, 120–132 h; third, 156–180 h. aPTT, activated partial thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase.

Main Article

1Current affiliation: Nicosia State Hospital, Burhan Nalbantoglu General Hospital, Nicosia, Cyprus.

Page created: December 07, 2022
Page updated: January 21, 2023
Page reviewed: January 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external